FGR
Overview
FGR encodes a non-receptor tyrosine kinase of the SRC family (also known as Gardner-Rasheed feline sarcoma viral oncogene homolog). FGR plays roles in immune cell signaling, particularly in myeloid cells. In cancer, FGR can be dysregulated through gene fusions driven by promoter-swap mechanisms that place its kinase domain under a strong heterologous promoter.
Alterations observed in the corpus
- FGR–WASF2 fusion: Detected in seven samples across the TCGA pan-cancer fusion atlas (9,624 samples, 33 cancer types). The WASF2 5′UTR promoter drives FGR overexpression in five of seven fusion-positive samples, supporting a promoter-swap activation mechanism. PMID:29617662
Cancer types (linked)
- Pan-cancer: FGR–WASF2 represents a recurrent singleton-pattern kinase fusion observed across the TCGA cohort; specific cancer type(s) were not individually named in the detailed narrative. PMID:29617662
Co-occurrence and mutual exclusivity
- No co-mutation pattern specifically reported for FGR in the corpus.
Therapeutic relevance
- FGR as a SRC-family kinase is potentially targetable by broad SRC/kinase inhibitors, but no specific therapeutic annotation is reported for FGR–WASF2 in the corpus. PMID:29617662
Open questions
- The cancer types harboring FGR–WASF2 fusions are not individually detailed; further characterization of the oncogenic dependency on FGR kinase activity in fusion-positive tumors is needed. PMID:29617662
Sources
This page was processed by crosslinker on 2026-05-15.